Ernest C. Borden

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +13

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

G. Thomas Budd, Massimo Cristofanilli, Mathew J. Ellis et al. · Clinical Cancer Research · 2006 · 787 citations

Medicine, Oncology, Radiology +17

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Michael C. Heinrich, Kouros Owzar, Christopher L. Corless et al. · Journal of Clinical Oncology · 2008 · 653 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Soft tissue sarcomas of adults: state of the translational science.

Ernest C. Borden, Laurence H. Baker, Robert S. Bell et al. · PubMed · 2003 · 616 citations

Medicine, Molecular Biology, Oncology +17

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.

Younan A. Sidky, Ernest C. Borden · PubMed · 1987 · 497 citations

Medicine, Immunology, Oncology +11